UNSPSC 51314330: Carbetapentane/phenylephrine/phenylpropanolamine/potassium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314330 Carbetapentane/phenylephrine/phenylpropanolamine/potassium is a Commodity code that sees limited recent state and local procurement activity aligned with its nominal pharmaceutical-combination scope. The recent opportunities tagged to this code instead reflect broader state and local purchasing of emergency response medications, generic pharmaceuticals, and pharmacy benefit program services rather than the specific drug combination the code names. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive bidding, Texas HHS has issued an exploratory RFI on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has sought manufacturers for generic multi-source pharmaceuticals and OTC products via RFP. The code shows little evidence of targeted procurement of the specific active-ingredient combination it names.

The geographic spread covers Florida, Texas, and Minnesota, with MMCAP's multistate cooperative vehicle extending reach to Oregon and other participating jurisdictions. Issuing bodies range from county health departments (Seminole County) to state health agencies (Texas HHS Commission) to multistate cooperative purchasing alliances (MMCAP). The representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone annually (response deadline Jul 26, 2023), Texas HHS's RFI on direct-to-manufacturer prescriptions (response deadline Apr 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products with proposals due Mar 26, 2026 and contract effectiveness Jul 1, 2026. The mismatch between the code's specific drug name and the actual scope of recent solicitations suggests the code may be a misapplication of the UNSPSC taxonomy to these opportunities, making it a weak signal for business development focused on the named pharmaceutical combination.